Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Change of operational policy

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon Dec 09, 2022 1:25am

181 Views

Post# 35161000

RE:RE:RE:RE:RE:RE:RE:Change of operational policy

The best news in years. Not the start of the clinical trial, but conducted without a partner.

I was discourage by the former statement that they was looking for a partner, which would be risky business if the partner turned out to be AbbVie.

The compound has potential to reduce the sales of Botox, therefore it would be much better to partner with a competitor, AbbVie could sign a deal and kill the compound.

Interesting times for sure. Potentially two diabetes deals before the end if the anti-aging clinical trial!

<< Previous

Bullboard Posts

Next >>

This battery metals stock is on a path to the global stage